---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-211920"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:36:44.550688+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CytomX Q1 rev $10.3M; cash $346.7M; Varseta-M dose optimization enrollment complete (40 pts)

## Summary
- Q1 revenue $10.3M vs $50.9M YoY; decrease driven by completion of BMS and Amgen collaborations.
- Cash $346.7M (Dec 31: $137.1M) includes $234.2M net from March equity offering; runway to at least 2H 2028.
- Varseta-M dose optimization enrollment completed (40 patients); data update in 2H 2026 to inform monotherapy dose and potential registrational trial in late-line CRC.
- Varseta-M + bevacizumab Phase 1 combo underway; initial data by 1H 2027; Phase 1/2 chemo combo starts 2H 2026.
- CX-801 (PROBODY IFNα2b) Phase 1 combo with Keytruda enrolling third dose level; initial combo data expected end 2026.

## SEC filing metadata
- accession: 0001193125-26-211920
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000119312526211920/0001193125-26-211920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000119312526211920/ctmx-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-211920
- JSON: https://secwatch.observer/filing/0001193125-26-211920.json
- Plain text: https://secwatch.observer/filing/0001193125-26-211920.txt

## Source-grounded claims
- claim_id: fd114a7d6583a6a52dcbcec76b5fd3d4d323bbbe
  claim: CytomX Therapeutics, Inc. reported for the quarter ended March 31, 2026 results: revenue 10.3 million.
  evidence_excerpt: Total revenue was $10.3 million for the quarter ended March 31, 2026, compared to $50.9 million for the first quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000119312526211920/0001193125-26-211920-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.